ZM323881, a Novel Inhibitor of Vascular Endothelial Growth Factor-Receptor-2 Tyrosine Kinase Activity

REFERENCES

• Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. (1998). Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk 1) and VEGF receptor 3 (F1t4). Proc Nall Acad Sci USA. 95:548–553.
   PubMed Web of Science ®Google Scholar
• Basser R, Hurwitz H, Barge A, Davis I, DeBoer R, Holden S, McArthur G, McKinley M, Nairn K, Persky M, Rischin D, Rosenthal M, Swaisland H, Eckhardt G. (2001). Phase 1 pharmacokinetic and biological study of the angiogenesis inhibitor, ZD6474, in pa-tients with solid tumors. In: Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology. American Society of Clinical Oncology, San Francisco, USA.
   Google Scholar
• Bates DO, Curry FE. (1996). Vascular endothelial growth factor increases hydraulic conductivity of iso- lated perfused microvessels. Am J Physiol 271: H2520–H2528.
   Google Scholar
• Bates DO, Lodwick D, Williams B. (1999). Vascular endothelial growth factor and microvascular perme-ability. Microcirculation 6:83–96.
   PubMed Web of Science ®Google Scholar
• Curry FE, Huxley VH, Sarelius IH. 1983. Techniques in microcirculation: measurement of permeability, pressure and flow. In: Cardiovascular Physiology. Techniques in the Life Sciences. Vol. P309. (RJ Lin-den, ed.) Elsevier, New York: pp. 1–34.
   Google Scholar
• de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. (1992). The fms-like tyrosine ki-nase, a receptor for vascular endothelial growth fac-tor. Science 255:989–991.
   PubMed Web of Science ®Google Scholar
• Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Mad-jar H, Muller M, Wood J, Martiny-Baron G, Unger C, Marme D. (2000). Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth fac-tor receptor tyrosine kinases, on primary tumor, me-tastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60:4819–4824.
   Google Scholar
• Flamme I, Breier G, Risau W. (1995). Vascular en-dothelial growth factor (VEGF) and VEGF receptor 2 (flk-1) are expressed during vasculogenesis and vas-cular differentiation in the quail embryo. Dev Biol 169:699–712.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. (2001). Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843–850.
   Google Scholar
• Guo D, Jia Q, Song HY, Warren RS, Donner DB. (1995). Vascular endothelial cell growth factor pro-motes tyrosine phosphorylation of mediators of signal transduction that contain 5H2 domains. Association with endothelial cell proliferation. J Biol Chem 270: 6729–6733.
   Google Scholar
• Hargrave RW, Huxley VH, Thipakorn B. (1995). Seasonal variations of capillary hydraulic conductiv-ity and volume status. Am J Physiol 268:R468–R474.
   Google Scholar
• Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Ple PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO, Kendrew J, Lambert-van der Brempt C. (1999). Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J Med Chem 42:5369–5389.
   PubMed Web of Science ®Google Scholar
• Hillman NJ, Whittles CE, Pocock TM, Williams B, Bates DO. (2001). Differential effects of vascular en-dothelial growth factor-C and placental growth fac-tor-1 on the hydraulic conductivity of frog mesenteric capillaries. J Vasc Res 38:176–186.
   Google Scholar
• Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. (1996). A novel vascular endothelial growth fac-tor, VEGF-C, is a ligand for the F1t4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:290–298.
   PubMed Web of Science ®Google Scholar
• Kendall RL, Wang G, DiSalvo J, Thomas KA. (1994). Specificity of vascular endothelial cell growth factor receptor ligand binding domains. Biochem Biophys Res Commun 201:326–330.
   PubMed Web of Science ®Google Scholar
• Kendall RL, Wang G, Thomas KA. (1996). Identifi-cation of a natural soluble form of the vascular en-dothelial growth factor receptor, FLT-1, and its het-erodimerization with KDR. Biochem Biophys Res Commun 226:324–328.
   PubMed Web of Science ®Google Scholar
• Ku DD, Zaleski JK, Liu S, Brock TA. (1993). Vascu-lar endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Phys-iol 265:H586–H592.
   PubMed Web of Science ®Google Scholar
• Lohmann J-JM, Hennequin LFA, Thomas AP. 1999. Preparation and antiangiogenic and/or vascular per-meability reducing effect of quinazoline derivatives. In: United States Patent Office. Zeneca Ltd, UK, USA.
   Google Scholar
• Michel CC, Curry FE. (1999). Microvascular perme-ability. Physiol Rev 79:703–761.
   PubMed Web of Science ®Google Scholar
• Michel CC, Mason JC, Curry FE, Tooke JE, Hunter PJ. (1974). A development of the Landis technique for measuring the filtration coefficient of individual capillaries in the frog mesentery. Q J Exp Phys Cog Med Sci 59:283–309.
   Google Scholar
• Olofsson B, Jeltsch M, Eriksson U, Alitalo K. (1999). Current biology of VEGF-B and VEGF-C. Curr Opin Biotechnol 10:528–535.
   PubMed Web of Science ®Google Scholar
• Olofsson B, Pajusola K, Kaipainen A, Von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Ali-talo K, Eriksson U. (1996). Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Nall Acad Sci USA. 93: 2576–2581.
   Google Scholar
• Park JE, Chen HH, Winer J, Houck KA, Ferrara N. (1994). Placenta growth factor. Potentiation of vas-cular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 269:25646–25654.
   PubMed Web of Science ®Google Scholar
• Pocock TM, Bates DO. (2001). In vivo mechanisms of vascular endothelial growth factor-mediated in-creased hydraulic conductivity of Rana capillaries. J Physiol (Lond) 534:479–488.
   Google Scholar
• Quinn TP, Peters KG, De Vries C, Ferrara N, Wil-liams LT. (1993). Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Nall Acad Sci USA. 90: 7533–7537.
   Google Scholar
• Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamagu-chi S, Shibuya M. (1995). A unique signal transduc-tion from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 10:135–147.
   Google Scholar
• Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. (1990). Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50:1774–1778.
   PubMed Web of Science ®Google Scholar
• Stacker SA, Vitali A, Caesar C, Domagala T, Groenen LC, Nice E, Achen MG, Wilks AF. (1999). A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability. J Biol Chem 274:34884–34892.
   PubMed Web of Science ®Google Scholar
• Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. (1994). Different signal transduction properties of KDR and Flt 1, two recep-tors for vascular endothelial growth factor. J Biol Chem 269:26988–26995.
   PubMed Web of Science ®Google Scholar
• Warner AJ, Lopez-Dee J, Knight EL, Feramisco JR, Prigent SA. (2000). The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells. Bio-chem J 347:501–509.
   PubMed Web of Science ®Google Scholar
• Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF. (2000). ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor effi-cacy. Cancer Res 60:970–975.
   PubMed Web of Science ®Google Scholar
• Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F. (2000). PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral ad-ministration. Cancer Res 60:2178–2189.
   PubMed Web of Science ®Google Scholar
• Wu HM, Huang Q, Yuan Y, Granger HJ. (1996). VEGF induces NO-dependent hyperpermeability in coronary venules. Am J Physiol 271:H2735—H2739.
   PubMed Web of Science ®Google Scholar
• Xu L, Yoneda J, Herrera C, Wood J, Killion JJ, Fidler U. (2000). Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 16:445–454.
   PubMed Web of Science ®Google Scholar
• Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ. (2000). Treatment for malignant pleural effusion of human lung adeno-carcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphoryla-tion. Clin Cancer Res 6:957–965.
   PubMed Web of Science ®Google Scholar